Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes. [electronic resource]
Producer: 20140519Description: 915-22 p. digitalISSN:- 1463-1326
- Adiponectin -- blood
- Blood Glucose -- metabolism
- Body Mass Index
- C-Reactive Protein -- metabolism
- Cyclohexanes -- therapeutic use
- Diabetes Mellitus, Type 2 -- blood
- Double-Blind Method
- Female
- Glycated Hemoglobin -- metabolism
- Hepatocytes -- metabolism
- Humans
- Hypoglycemic Agents -- therapeutic use
- Insulin -- therapeutic use
- Insulin Resistance
- Lipid Metabolism -- drug effects
- Lipolysis -- drug effects
- Male
- Middle Aged
- Nateglinide
- Phenylalanine -- analogs & derivatives
- Pioglitazone
- Sulfonylurea Compounds -- therapeutic use
- Thiazolidinediones -- therapeutic use
- Treatment Outcome
No physical items for this record
Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.